Sarepta Therapeutics Company Insiders
| SRPT Stock | USD 118.00 0.94 0.80% |
Sarepta Therapeutics employs about 1.3 K people. The company is managed by 13 executives with a total tenure of roughly 3066 years, averaging almost 235.0 years of service per executive, having 101.08 employees per reported executive. Breaking down Sarepta Therapeutics' management performance can provide insight into the firm performance.
Sarepta |
Sarepta Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of 0.0151 % which means that it generated a profit of $0.0151 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1227 %, meaning that it created $0.1227 on every $100 dollars invested by stockholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Sarepta Therapeutics Workforce Comparison
Sarepta Therapeutics is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 4,891. Sarepta Therapeutics totals roughly 1,314 in number of employees claiming about 27% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.05 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.05. Sarepta Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sarepta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sarepta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sarepta Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sarepta Therapeutics Notable Stakeholders
A Sarepta Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sarepta Therapeutics often face trade-offs trying to please all of them. Sarepta Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sarepta Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Douglas Esq | CEO President | Profile | |
| Ian Estepan | Executive CFO | Profile | |
| Ryan JD | General VP | Profile | |
| Will Tilton | Head VP | Profile | |
| William Ciambrone | Ex Operations | Profile | |
| Dallan Murray | Executive Officer | Profile | |
| Louise RodinoKlapac | Chief VP | Profile | |
| Alison Nasisi | Executive Officer | Profile | |
| Bilal Arif | Executive Officer | Profile | |
| Diane Berry | Executive Officer | Profile | |
| Ryan Brown | Gen VP | Profile | |
| Mary Jenkins | Senior Relations | Profile | |
| Francesca Nolan | Executive Communications | Profile |
About Sarepta Therapeutics Management Performance
The success or failure of an entity such as Sarepta Therapeutics often depends on how effective the management is. Sarepta Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sarepta management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sarepta management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Sarepta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 840 people.
Please note, the imprecision that can be found in Sarepta Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sarepta Therapeutics. Check Sarepta Therapeutics' Beneish M Score to see the likelihood of Sarepta Therapeutics' management manipulating its earnings.
Sarepta Therapeutics Workforce Analysis
Traditionally, organizations such as Sarepta Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sarepta Therapeutics within its industry.Sarepta Therapeutics Manpower Efficiency
Return on Sarepta Therapeutics Manpower
| Revenue Per Employee | 946.2K | |
| Revenue Per Executive | 95.6M | |
| Net Loss Per Employee | 407.9K | |
| Net Loss Per Executive | 41.2M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 148.1M |
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.